
Explore the history of Celgene.

David Stirling, Ph.D. and Sol Barer, Ph.D. team up at Celanese Corporation, a chemical company.

Celgene spins off from Celanese and becomes an independent biotechnology company.

Celgene's initial public offering (IPO) on the NASDAQ exchange.

Celgene licenses patent for uses of thalidomide from Rockefeller University.

Celgene scientists research and develop numerous compounds based on the structure of thalidomide.

Dr. Sol Barer named President and Chief Operating Officer.

Receives U.S. Food and Drug Administration (FDA) approval for expanded access to THALOMID (thalidomide).

John W. Jackson, who had worked at Merck and American Cyanamid, joins Celgene and is named Chief Executive Officer.

Receives FDA additional approval to market THALOMID?.

Celgene works with the FDA to develop the industry's first Risk Evaluation and Mitigation Strategy (REMS) to avoid embryo-fetal exposure.

Bob Hugin joins Celgene from J.P. Morgan & Co. Inc and becomes Chief Financial Officer.

New England Journal of Medicine publishes landmark paper on THALOMID? (thalidomide).

Celgene develops FOCALIN? with Novartis and receives FDA approval.

Celgene acquires Anthrogenesis and renames the unit Celgene Cellular Theraputics (CCT).

REVLIMID? (lenalidomide)—an IMiD? compound— is discovered and developed in Celgene's own labs and approved by the FDA.

FOCALIN XR?, an extended release formulation developed with Novartis, is approved by the FDA for an additional use.

Dr. Sol Barer becomes Chief Executive Officer.

Completion of International Headquarters in Boudry, Switzerland.

THALOMID? (thalidomide) plus dexamethasone receives FDA approval.

FDA approves REVLIMID? (lenalidomide) plus dexamethasone.

European Medicines Agency (EMA) and the Swiss Medic approves REVLIMID? (lenalidomide) plus dexamethasone for an additional use.

Celgene acquires Pharmion and begins marketing VIDAZA.

EMA approves VIDAZA?

Celgene and Acceleron Pharma announce research collaboration to develop therapies for cancer and other rare diseases.

Bob Hugin becomes Celgene's Chief Executive Officer.

Celgene acquires Gloucester Pharmaceuticals, and begins marketing ISTODAX? (romidepsin).

Celgene acquires Abraxis BioScience and gains rights to ABRAXANE? (paclitaxel protein-bound particles for injectable suspension).

Celgene and Agios Pharmaceuticals, Inc. announce global strategic collaboration focused on targeting cancer metabolism.

FDA approves ISTODAX? (romidepsin) for an additional use.

FDA approves ABRAXANE? (paclitaxel protein-bound particles for injectable suspension) for an additional use (alt: indication, patient population).

FDA approves IMiD? compound POMALYST? (pomalidomide).

Celgene and bluebird bio enter into strategic research collaboration to develop novel therapies in oncology.

OTEZLA? (apremilast) is approved by the U.S. FDA

OTEZLA? (apremilast) is approved by the U.S. FDA for an additional use.

FDA approves REVLIMID? (lenalidomide) plus dexamethasone for an additional use.

Celgene acquires San Diego, CA based Receptos Inc., adding ozanimod - an investigational oral agent in Phase III trials for relapsing / remitting Multiple Sclerosis (RRMS) and Inflammatory Bowel Disease (IBD).

Celgene and Juno Therapeutics enter into strategic research collaboration focused on the development of CAR T therapies

Mark Alles is promoted to Chief Executive Officer and Bob Hugin becomes Executive Chairman.

REVLIMID? (lenalidomide) is approved by the European Commission for an additional use.

Celgene and collaborative partner Juno Therapeutics received breakthrough designation for investigational drug JCAR017 from the U.S. FDA and Priority Medicines Eligibility from the EMA for relapsed/refractory DLBCL.

The U.S. FDA and European Commission approve REVLIMID? (lenalidomide) plus dexamethasone for an additional use.

Celgene launches IDHIFA? (enasidenib)

Acquisition of IMPACT BioMedicines and their therapy fedratinib for patients with myelofibrosis.

Executive Chairman Bob Hugin Retires. Mark Alles appointed Chairman of the Board of Directors.
